Back to the atlasDownload source notes

September 22, 2026 — scheduled research update (retry)

Home · Latest · Calendar

The morning attempt stopped before completion; this evening retry resumes that check. Research through September 22; final verification UTC 2026-09-23T04:17:35Z. Searched from the last successful checks with a seven-day overlap, prioritizing September 18–22. Older additions retain original dates and baseline labels.

46 deduplicated sourced entries, three new attributed informal signals, and 28 focused topic checks. Coverage remains partial; successful-check timestamps are preserved where gaps remain. This is not an exhaustive review or an all-topic no-news conclusion.

Meaningful findings

Coverage and remaining gaps

Whole-body MRI

Status: focused, partial. Refreshed HERCULES original registry, searched September human screening-outcome reports and upcoming trials; no new outcome verified in reviewed sources.

Gaps: HERCULES retains April 2025 verification and no results; actual ongoing recruitment unverified. Cochrane item is an August review protocol, not outcome evidence. Full repeat-screening literature and all screening cohorts not reappraised.

Informal sources: Flex Diet episode405 September21 show notes and timestamp list checked; educational discussion, no new trial result or concrete new rumor. Full audio not reviewed. https://podcasts.apple.com/nz/podcast/episode-405-whole-body-mri-ct-scans-and-what-imaging/id1488376804?i=1000790902903

Sources checked: Source 1; Source 2.

Galleri and organ-specific cancer screening

Status: focused, partial. Read FDA meeting, exact voting/discussion questions, revised-assay performance and workup safety sections; discovered September22 repeat-round performance paper. Prior missing briefing gap materially closed.

Gaps: Full sponsor briefing, all FDA subgroup appendices, organ-specific screening interval outcomes and mortality publications not fully reappraised. Meeting has not occurred at check.

Informal sources: September21 Reddit market commentary calls briefing favorable; that inference is not an FDA endorsement. Automated secondhand CEO timing attribution lacked an original source and was not promoted. https://www.reddit.com/r/Wiseek/comments/1wmi37e/gral_fda_briefing_doc_backs_galleri_cancer_test/

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7.

Cancer treatment, vaccines and recurrence prevention

Status: focused, partial. New oncology program/results discovery; verified VNX101 release and registry, intismeran ESMO schedule; original event dates retained.

Gaps: Full WCLC/PAPILLON/COPERNICUS tables, all ADC/radiopharmaceutical programs and new oncology labels not systematically reappraised. VNX101 detailed safety grades unavailable.

Informal sources: ModernaStock repost merely repeats original ESMO notice; SELLAS investor discussion/speculation did not establish new data or a confirmed REGAL readout date. https://www.reddit.com/r/ModernaStock/comments/1wme0iz/moderna_announces_latebreaking_data_to_be/

Sources checked: Source 1; Source 2; Source 3.

Autoimmune disease modification and immune-reset therapies

Status: focused, partial. Verified EMA gefurulimab opinion; sought rap-cel/zola-cel restart, in-vivo programs and informal investigator planning.

Gaps: No verified rap-cel/zola-cel autoimmune restart. Full in-vivo CD19 September2 NEJM letter and all trial registries not reappraised.

Informal sources: OncLive September22 institutional planning signal recorded separately. BioCentury episode388 September21 and Can Do MS episode207 September9 surfaced, but full recordings not reviewed. https://biocentury.buzzsprout.com/1035190/episodes/19842477-ep-388-biotech-ipos-car-t-safety-pharma-tariffs

Sources checked: Source 1; Source 2.

Allergy and airway disease

Status: focused, partial. Recovered September15 rademikibart primary-endpoint miss; verified original registry and VIASKIN filing forecast.

Gaps: Rademikibart exploratory-subgroup full paper inaccessible; all ERS abstracts/environmental-allergy studies not fully reviewed. No original COPD topline or actual VIASKIN BLA submission verified.

Informal sources: September8 Reddit discussion anticipated September readouts and correctly distinguished FEV1 from primary treatment failure; later actual result recorded separately, not rumor confirmation of efficacy. Bio Report190 Sept2 describes preclinical allergy CAR-T work, no verified human trial. https://www.reddit.com/r/biotech_stocks/comments/1waqxwm/cntb_has_two_phase_2_results_coming_this_month/

Sources checked: Source 1; Source 2; Source 3; Source 4.

Infectious-disease prevention and treatment

Status: focused, partial. Verified ARIKAYCE priority-review action and searched human antibiotic/phage/new-class/vaccine/antiviral developments.

Gaps: Full ENCORE numerical tables and broad human antibiotic/antiviral registries not comprehensively refreshed; phage-antibiotic laboratory work excluded. Actual Utebzi launch not independently verified.

Informal sources: Targeted phage/antibiotic Reddit and podcast searches did not supply a usable new human-stage rumor; indexed search is incomplete, not proof no signal exists.

Sources checked: Source 1.

Genetic screening and risk prediction

Status: focused, partial. Verified new-to-watch T1D polygenic-risk screening registration; searched PRS/PGT/newborn/PGx research and deduplicated September 8 non-invasive PGT-A trial.

Gaps: Full SPLENDID/newborn/PGx/cascade-testing inventory remains partial. The PGT-A cohort abstract was appraised; full-paper methods, adjusted comparisons and long-term offspring follow-up remain unreviewed. No generic embryo-safety claim is inferred.

Informal sources: September 18 IVF discussion linked primary PGT-A research; avoid adopting commenters’ generalized efficacy claims or treating clinic anecdotes as trials. https://www.reddit.com/r/IVF/comments/1wk6bz5/new_study_17_lbr_for_segmental_aneuploid_embryos/

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Bone health, joint preservation and cartilage repair

Status: focused, partial. Refreshed NVD003 original pivotal registry and searched EB613/lorecivivint/cartilage and fracture outcomes.

Gaps: No actual lorecivivint submission or new EB613 start verified. Full10-person engineered-cell paper and pamidronate low-back-pain paper remain unappraised; no negative or positive conclusion added from headlines.

Informal sources: Reddit osteoporosis engineered-cell discussion repeats existing September15 report; no new verified start or durable-outcome rumor found. https://www.reddit.com/r/science/comments/1whfv3z/a_living_medicine_made_from_genetically/

Sources checked: Source 1; Source 2.

Non-opioid acute and chronic pain therapies

Status: focused, partial. Refreshed newly noticed suzetrigine pelvic-surgery protocol; searched chronic/neuropathic non-opioid developments, with CagriSema neuropathy and CBL514 Dercum results cross-linked from metabolic review.

Gaps: Pelvic-surgery trial is older May registration, not yet recruiting; November1 start/July2027 primary completion remain estimates. Full PAINWeek Mohs tables, VX993/Tonmya and all new mechanisms not fully reviewed.

Informal sources: September21 CRPS Journavx discussion is individual off-label experience, not a new trial or reliable efficacy rumor. https://www.reddit.com/r/CRPS/comments/1wlyinj/journavx/

Sources checked: Source 1; Source 2; Source 3.

Status: focused, partial. September 5–22 overlap; Viking maintenance, Novo CMD/readouts, EASD timing, human-development announcements and fresh registries. Priority September 18–22.

Gaps: Full tables/CIs and treatment-policy estimands for new CagriSema trials unavailable. VK2735-102 NCT identifier not matched; exact registry phase not asserted. Not a complete global registry/conference census; no full webcast audio review.

Informal sources: Targeted Reddit and management-talk searches; today's VK2735 discussion mainly repeats the official release. Novo investor posts do not establish unpublished readouts. CagriSema neuropathy cross-reported once in pain.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7.

Muscle building and preservation

Status: focused, partial. Rechecked bimagrumab/tirzepatide, COURAGE, PLATEAU and SRK forecasts; found a separate historical Columbia bimagrumab study. Distinguished registry changes from mirror-refresh dates.

Gaps: Lilly bimagrumab/tirzepatide Phase 2 has no posted results; full release-date search and functional endpoints remain incomplete. COURAGE registry total actual enrollment 1005 differs from the 599 initial readout cohort; do not conflate. Original Cantor webcast audio not reviewed; third-party transcript only. Sarcopenia/disease-specific pipeline census incomplete.

Informal sources: Read September 9 Investing.com transcript of Veru Cantor discussion; captured explicitly informal Phase 3 scale/functional-endpoint direction. Reddit queries mostly returned gray-market questions or prior data, excluded. Existing PLATEAU Q1 2027 interim forecast repeated, not re-alerted.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Longevity and healthspan drug trials

Status: focused, partial. TAME direct status, rentosertib September 7 proteomics paper, rapamycin RESTOR and AgelessRx pilot/APOE4 registry follow-up.

Gaps: TAME actual launch/registration remains unverified; official page still fundraises to launch. AgelessRx larger planned 186-person study registration not confirmed; old 30-person record has elapsed unrefreshed estimate. Rentosertib full parent-trial safety not separately reconstructed; proteomic changes are not healthspan outcomes. Senolytic/metformin worldwide registry census and complete podcasts not covered.

Informal sources: Targeted Reddit/rapamycin/podcast/TAME searches. Excluded animal-only items and unsupported TAME interim-result blog claims lacking a retrievable original study, conflicting with AFAR launch status. Did not treat search popularity/reposts as corroboration.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Localized fat removal

Status: focused, partial. CBL-514 Dercum original readout, SUPREME-01 current status, RZL-012/AYP-101/tesamorelin and cellulite registry/source discovery.

Gaps: Full Dercum arm denominators, CIs and safety table absent; larger-trial timing unknown. No independently verified new RZL-012 result or tesamorelin new-indication result; aesthetic device comparative census incomplete. September 30 visceral-fat presentation has not occurred within this check.

Informal sources: Targeted CBL-514/tesamorelin/cellulite Reddit and talk searches mainly returned personal experience, gray-market sourcing and promotion; excluded. Sponsor lipedema feasibility statement remains a plan, not an active trial.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Broad cardiovascular prevention, lipid therapies and screening

Status: focused, partial. EU obicetrapib announcement/EMA opinions; Novo oral PCSK9/GLP-1 plan; VERVE-102, Lp(a) outcome registries, new lipid entrants and ARO-DIMER target correction. Cross-topic ZEUS/EASi gaps.

Gaps: Formal European Commission decision and updated final obicetrapib SmPC not retrieved; authorization is sponsor-announced. PREVAIL old completion estimate is not a confirmed readout schedule; no new results. VERVE Phase 2 initiation and full ASCVD screening/CAC/CCTA/AI-plaque census incomplete. MWX203 precise target mechanism not verified, so not assigned from biomarker lists.

Informal sources: Obicetrapib approval lead corroborated by original sponsor. Existing Attia/Davidson Alzheimer's-prevention hypothesis has no newly verified clinical outcome; root/Alzheimer's topic owns unchanged rumor. Investor posts and republished ZEUS news not counted as new findings.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11; Source 12; Source 13.

Liver disease, fibrosis and noninvasive assessment

Status: focused, partial. Novo September 21 MASH/ALD plans, EMA September meeting, efruxifermin registry timing, TGM-312 registry-identifier recovery and ATHENA status gap.

Gaps: Wegovy September EU procedure outcome not explained in retrieved CHMP highlights; no approval/rejection inferred. ATHENA discontinuation lead not resolved by current primary record, which still predates alleged news. SYNCHRONY RW completion windows elapsed without posted result; no assumed readout. Noninvasive liver-test outcome/comparative census incomplete; no full CMD audio review.

Informal sources: Read September 18 original Reddit post noticing Wegovy's absence from meeting highlights; verified agenda/absence and retained outcome uncertainty. New CMD liver plans are sourced to official slides, not Reddit interpretation.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9.

Kidney preservation and earlier CKD detection

Status: focused, partial. Recovered September 15 EASi-KIDNEY negative development and ORIGIN 3 final readout, September 14 ebribafusp first-dose announcement; finerenone/new kidney trial registries and BEAT-PKD gap.

Gaps: Detailed final ORIGIN 3 arm-level safety/estimand/composite definitions need congress/publication; FDA full-approval action not yet occurred. EASi-KIDNEY registry remains active/not recruiting while sponsor announced stopping; status is administrative, not proof that decision reversed. BEAT-PKD estimated September 21 start elapsed while registry says not yet recruiting; actual dosing not verified. Kidney early-detection and global disease-specific census incomplete; full audio sources not reviewed.

Informal sources: Read Reddit kidney/ADPKD/lupus trial discussions: self-identified VX-407 participant's mixed cyst-diameter anecdotes do not establish trial efficacy; trial-intake and transplant posts are leads, not outcome announcements. Primary sponsor/registry evidence used for included findings.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9.

Alzheimer's screening and therapies

Status: focused, partial. Read full topic, baseline/state and September18 gaps; September5–22 treatment, blood-test, human prevention, safety/negative searches. Verified SPINOZA original registry and FDA PrecivityAD2 clearance, appraised p-tau217/APOE original abstract and investigator discussion. Revisited Attia/Davidson original notes. Earlier ALZ101, PrevenTRON and tau-platform entries deduplicated.

Gaps: Exact ALZ101 phase2 and PrevenTRON registry matching remains unresolved. All current anti-amyloid labels/recall-database changes and older lithium/XPro/external-counterpulsation full papers were not comprehensively appraised. SPINOZA registration is verified but actual enrollment/start is not; September estimate is not confirmation. Full p-tau217/APOE paper not accessed; original abstract used. Grifols forthcoming November RWE presentation identified, without new numerical results to appraise.

Informal sources: Rechecked the original September14 Attia/Davidson episode chapter notes; registered-study existence now verified independently, preventive benefit remains a hypothesis. Targeted recent Reddit Alzheimer/biomarker queries mostly personal anecdotes or reposts; no separate new verified efficacy rumor extracted. Full podcast/transcript sweep remains incomplete.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Status: focused, partial. Read full topic and prior gaps; September5–22 human-stage, safety and regulatory searches. Appraised bipolar-II pilot, Optimi original phase2/3 planned-trial releases, FDA hearing page and original MDMA report/MAPS response. Previously reported Panorama, COMP005 and personality-disorder subgroup deduplicated. Checked L-130 lead against older 2023 study/2024 publication context.

Gaps: FDA September14 full proceedings/transcript still not appraised. Official page checked; October5 comment deadline retained. No new binding policy/product approval inferred. Definium actual Psych Congress files and new analyses, GH001 phase3 registration and complete Helus/BPL003 status sweep remain gaps. Optimi registry IDs and design details not matched. L-130 planned September16 presentation not obtained; older ten-person phase1a results must not be relabeled new September efficacy. U.S. MDMA filing acceptance, decision date and approval remain unverified.

Informal sources: Existing anonymous-source Resilient report and MAPS original response rechecked: MAPS expressly responds to reported refiling and says it has no active role in Resilient development. Reposts are not independent confirmation. September18 Alaina Jaster hearing commentary appraised as participant/observer interpretation, not FDA policy; no new approval-date rumor promoted. Original talk/podcast coverage remains selective.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Mental-health treatments, SSRIs and newer antidepressants

Status: focused, partial. Read full topic and September18 gaps; searched MDD/anxiety/OCD/PTSD/bipolar/addiction human results, safety and new programs through September22. Closed numerical lumateperone mania gap with original poster/release and registry; appraised the small VTA neurofeedback trial and cross-linked bipolar-II psilocybin/Optimi programs. Prior PIPE307 negative result and emotional-blunting/KetSet registrations deduplicated.

Gaps: No distinct new 2026 seltorexant numerical randomized result verified: J&J 2026 index exposes burden/management observational posters; the easily found MDD3005 comparison is dated September22,2025. Do not relabel it 2026. Liafensine phase3 and ansofaxine U.S. development not fully refreshed; all OCD/PTSD/addiction programs not exhaustively checked. Older Ket-BD/RECOVER and OCD epigenetic full-text appraisal remain incomplete. VTA neurofeedback detailed adverse-event analysis not located.

Informal sources: Targeted Reddit seltorexant/mental-health searches found anecdotes and gray-market discussion (excluded), without a distinct source-grounded new program rumor. Original clinician talk/podcast sweep incomplete.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Sleep therapies and sleep disorders

Status: focused, partial. Read full topic and Sep18/Sep19 updates. Verified new vornorexant publication/Japan approval context; rechecked Orzeyful official pending-availability language, FDA label and Federal Register API for scheduling; inspected current original Brilliance3/Vibrance3/Neuro-DORA registry records. Targeted insomnia, OSA, hypersomnolence, circadian and RLS searches.

Gaps: Federal Register exact-name API searches returned no oveporexton/Orzeyful records; this is a negative search, not proof that no regulatory action exists. November launch remains sponsor forecast pending DEA. Exact vornorexant long-term trial registry/full safety tables not matched. Daridorexant daytime-function study registry/start and tasimelteon hearing outcome remain unresolved. Complete CBT-I/digital/circadian/RLS registry refresh and RLS conference late-breakers incomplete. Wearable insomnia meta-analysis identified as secondary synthesis, not a new drug trial; no new primary-result claim promoted.

Informal sources: Recent Reddit Orzeyful threads mostly repeat pending launch, access concerns and individual experiences; no independently supported new launch/scheduling rumor extracted. Seltorexant gray-market material excluded. Original podcast sweep incomplete.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11; Source 12; Source 13.

Hearing and vision preservation/restoration

Status: focused, partial. Read topic and prior gaps; searched inherited/acquired hearing and vision programs, safety/negative studies and entrants through September22. Verified Paliroden REACT registration; rechecked original AC102, Rincell, PST611 and BIRD1 records. Reviewed older terminated Roche geographic-atrophy and Regeneron uveitis entries as baseline leads, not new September terminations. BGE102/BEST1/PST611 prior events deduplicated.

Gaps: PRIMA/Otarmeni latest labels, regulator safety and commercial availability not comprehensively refreshed. SENS601 August31 authorization/Annexon ARCHERII original older leads and ACHIEVE secondary biomarker full paper still need appraisal. AC102 original record remains January16 snapshot with elapsed July31 completion estimate, not confirmation of phase3/tinnitus plans. PST611 registry enrolled8 vs sponsor treated6 remains a denominator clarification. Recovered RO7669330 GA termination (last posted Aug10: dose-limiting AEs reached stopping criteria) and REGN7041 TITAN uveitis termination (Aug17: unfavorable benefit-risk) are older baseline leads without AE details; consider future baseline additions, not this week’s alerts.

Informal sources: Original Aug29 AC102 secondhand-email thread revisited; no official confirmation of phase3/tinnitus 2027 claim located. September18 Paliroden Reddit lead traced to original registry and promoted as formal registration, not rumor. Additional informal searches were selective.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Hair loss and hair restoration

Status: focused, partial. Read full current topic, including September 19 mechanism-primer changes; searched September 5–22 original papers, sponsor releases, registries, new programs, alopecia areata and biological graying. Refreshed AWAKEN/HEADLINE and new KeraFactor/Revian records. Added Q32 presentation timing and appraised a new publication of an older deuruxolitinib dosing trial. PP405 still not yet recruiting; existing forecasts were not re-alerted.

Gaps: Kintor original HKEX index and March/September filings found; the August interim PDF failed in browser text, and a matched Chinese pivotal registry remains unresolved. No new GT20029 late-stage start verified. Deuruxolitinib full paper not appraised; registry already had results from the older trial, so publication must not be treated as fresh trial completion. A September 15 maresin-1 canities/vitiligo mechanism paper used human profiling but intervention experiments in mice and cells; excluded as human-treatment news. BioQ candidate-specific registry and dated human results remain unverified. No comprehensive updated alopecia-areata regulatory safety-label inventory or full investor-call transcript review.

Informal sources: Targeted Reddit/podcast/talk searches included PP405 registration discussion and ABS-201 investor speculation. Funding and registry estimates do not establish efficacy or first dosing. Original clascoterone and BQ-002 timing posts plus sponsor text rechecked; both remain unconfirmed with no repeat alert.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11; Source 12; Source 13; Source 14.

Skin aging, laxity and regeneration

Status: focused, partial. Searched September 5–22 human rejuvenation, laxity, topical, energy-device and safety papers; appraised the randomized IPL pilot. Refreshed KB304 registry, which still has stale 2025 estimates, and searched sponsor updates. September 17 Allergan small skin-care studies already recorded and deduplicated.

Gaps: September 22 multimodal RF/microneedle-RF/muscle-stimulation trial abstract lacks sample size and numerical effects; full paper not appraised, so no efficacy alert promoted. Allergan September 17–20 conference window has elapsed; no full poster/safety tables recovered. This does not prove presentation or positive completion. FDA RF safety communication was not freshly appraised in this run; rare-harm surveillance remains incomplete.

Informal sources: Searched Reddit and podcasts. September 7 Skinside Out description discusses existing retinoids, devices and cosmetic products; no attributable new clinical-development prediction. Full audio/transcripts not reviewed. Old 2025 KB304 call remains superseded by already recorded August 2026 guidance.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5.

Scar prevention, treatment and stretch marks

Status: focused, partial. Searched human scar prevention, established scars, keloids, stretch marks, new antifibrotic/vesicle programs and negative findings. Added randomized dry-needling result and preliminary nanovesicle combination pilot. Refreshed both verteporfin records and siRNA registry; searched Syntara updates.

Gaps: September 8 SPARC/IL4-RA siRNA full research letter remains inaccessible. No efficacy conclusion drawn. Verteporfin records remain not yet recruiting with stale estimates. Syntara Phase 1 scar-program identifiers and completion of Q3 recruitment remain unverified. Scar-needling full safety data and nanovesicle pilot full methods, numerical changes and registration remain gaps.

Informal sources: Targeted Reddit and podcast/talk searches found repeated August registry interpretations and self-experimentation/case anecdotes. No new specific formal-development rumor was selected. A search result containing a September 23 future-dated comment was excluded from this September 22 check.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11.

Facial volume restoration and contour

Status: focused, partial. Searched new filler, fat-graft, biostimulator, volume-restoration and safety evidence. Retrieved and appraised full September 14 KPRE/Adipeau paper and original trial registry, keeping lab mechanisms separate from the uncontrolled 35-person human imaging study.

Gaps: KPRE paper has no usable adverse-event table and no randomized replication; prespecified elasticity was not measured. September 18 self-protecting HA filler work is preclinical; not promoted to a new human therapy. No comprehensive fresh worldwide FDA/device-clearance or delayed-filler-complication inventory. Earlier HA-collagen RCT reporting discrepancy remains unresolved.

Informal sources: Searched Reddit, podcasts and talks. September 15 Adam Lamb/Neal Deot episode description discusses facial fat grafting and GLP-1-associated changes without a new trial milestone. September 14 GLP-1 Hub/Brian Pilcher description located, but full page/transcript fetch failed. No quotation or unverified development date invented.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Pigmentation and uneven skin tone

Status: focused, partial. Searched human melasma, PIH, solar spots and vitiligo papers; appraised new-to-notebook September 7 KT-939 safety announcement and September 22 Incyte EADV schedule. Refreshed STOP-V1/V2 records; no newly posted registry results. Prior melasma pilot/PRP findings deduplicated.

Gaps: September 19 ruxolitinib-versus-tacrolimus prospective paper and September 13 graft-versus-cell-suspension vitiligo report had no original abstracts; full results inaccessible and not inferred from titles. September 21 picosecond laser melasma abstract reviewed: retrospective 29 women, 12-week follow-up, no comparator. Full tables unavailable; minor series was not promoted. KT-939 disposition from 130 originally enrolled to 114 continuous users, complete adverse-event accounting and matched registry remain unresolved.

Informal sources: Reddit and podcast searches found personal tranexamic-acid/hydroquinone experiences and procedure discussions rather than a traceable new formal-program timing or efficacy rumor. No personal anecdote was recast as controlled evidence.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7.

Acne and rosacea

Status: focused, partial. Searched original September 5–22 acne/rosacea papers, investigational vaccine, topical drugs, devices, safety and sponsor developments. Refreshed SP0268 and rosacea redness-study records; their recruiting statuses/dates remain unchanged. No new material efficacy or regulatory result was verified within this focused check.

Gaps: September 17 topical-ruxolitinib rosacea case series and September 11 spruce-extract exploratory report were located; full methods/safety not appraised and no indication-level efficacy conclusion made. An isotretinoin-study correction was indexed September 5; its material effect on results not resolved in this pass. No complete new worldwide device-clearance review or SP0268 investigator update beyond the registry.

Informal sources: Targeted Reddit, podcast and talk queries. September 17 Dr Mitch Shulman radio-podcast segment is general acne-versus-rosacea discussion; episode notes lack a trial claim and no audio transcript was reviewed. No new attributable SP0268 rumor selected.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Dental alignment, regeneration and repair

Status: focused, partial. Searched human aligner/braces materials, clinical outcomes, monitoring, acceleration, retention, root/gum health, regeneration and repair. Appraised negative wear-sensor RCT, LightForce comparative cohort and cell-adjunct orthodontic pilot. Rechecked printed-aligner and new self-ligating comparison registries, and Toregem primary news.

Gaps: The September 20 final-completion estimate for NCT07496892 has now elapsed; record still not yet recruiting, last updated March 27, and no results. Remove any implication that the study completed. Toregem jRCT Phase 1 original page again returned 403; Phase IIa dosing and a matched registry remain unverified. Sponsor news still ends with August leadership/trial-notification events. Wear-sensor paper versus registry enrollment discrepancy (58 versus 52) unresolved; full comparative papers and complete safety/root/retention outcomes not appraised. New Bangladesh university aligner-versus-braces study is listed ongoing September 2026–August 2027, but design details and matched registry remain unverified; not promoted as an efficacy event. NCT07638397 was posted earlier and remains not yet recruiting despite September 15 estimated start.

Informal sources: Targeted Reddit and podcast searches. September 14 Kliq This episode description repeats speculative tooth-regrowth-by-2030 discussion; no named new clinical source or verified transcript. Promotional aligner-speed posts and old generic tooth-regrowth forecasts were not repeated as new signals.

Sources checked: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11; Source 12.

Corrections and unresolved informal claims

ARO-DIMER-PA targets PCSK9/APOC3; the older Latest preview incorrectly said ANGPTL3. Corrected the preview to match the original Arrowhead source and topic notes; this is an editorial correction, not a new trial result.

Existing clascoterone, BQ-002, AC102, Resilient and obicetrapib-benefit claims were revisited. No new efficacy or approval confirmation is inferred. SPINOZA registration closes a program-existence gap only. Veru’s possible enobosarm phase 3 design is an informal management statement, and Wegovy’s omitted CHMP mention leaves the MASH outcome unresolved; neither is an FDA or EMA commitment. The new OncLive IBD planning signal is attributed to an indexed discussion summary, with original-video access limitations explicit.

Website edition

The notebook was verified before export. This update refreshes topic summaries, milestone previews, and affected charts; publication is tracked separately from research verification. The public edition excludes personal notes and identifying context.